CompletedPhase 3NCT00005867
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lymphoma Trials Office
- Principal Investigator
- Ruth Pettengell, MDSt. George's Hospital
- Intervention
- bleomycin sulfate(biological)
- Enrollment
- 310 enrolled
- Eligibility
- 18-59 years · All sexes
- Timeline
- 1998 – 2007
Study locations (30)
- Stoke Mandeville Hospital, Aylesbury-Buckinghamshire, England, United Kingdom
- Horton Hospital, Banbury, England, United Kingdom
- Basildon University Hospital, Basildon, England, United Kingdom
- Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
- Bradford Hospitals NHS Trust, Bradford, England, United Kingdom
- Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
- Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
- Cheltenham General Hospital, Cheltenham, England, United Kingdom
- Countess of Chester Hospital NHS Foundation Trust, Chester, England, United Kingdom
- Saint Richards Hospital, Chichester, England, United Kingdom
- Essex County Hospital, Colchester, England, United Kingdom
- Walsgrave Hospital, Coventry, England, United Kingdom
- Russells Hall Hospital, Dudley, England, United Kingdom
- Chase Farm Hospital, Enfield, England, United Kingdom
- Medway Maritime Hospital, Gillingham Kent, England, United Kingdom
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005867 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic